DuPont Herbert L
Center for Infectious Diseases, University of Texas Medical School and School of Public Health, 6431 Fannin, 1.729JFB, Houston, Texas, 77030, USA.
Drugs. 1993 Jun;45(6):910-917. doi: 10.2165/00003495-199345060-00004.
For those who venture from highly industrialised areas to developing tropical and semitropical areas, the chance of developing diarrhoea is about 40%. In most cases a bacterial pathogen is responsible for the illness. The antimicrobial agents with the greatest activity against these organisms are cotrimoxazole (trimethoprim/sulfamethoxazole) during the summer months in the interior of Mexico (a region where this agent has been studied extensively), and the fluoroquinolones for other places or other times, until data become available to indicate the appropriateness of cotrimoxazole here as well. Persons at risk should take along with them a drug to treat symptoms of travellers' diarrhoea, and an appropriate antimicrobial agent. At the passage of the third unformed stool, it is recommended that travellers treat themselves with fluids and salt (flavoured mineral water augmented with saltine crackers is sufficient in most cases), symptomatic treatment and antibacterial therapy. Of these, the antimicrobial is the most important component, which is given either as a single large dose or one or twice daily for 3 days. Perhaps optimal therapy for afebrile nondysenteric patients is loperamide in combination with the antibacterial drug. In the face of fever or dysentery, the antimicrobial should be used alone. In special situations where food and beverage restrictions cannot be followed and where the itinerary cannot tolerate even the slightest alterations because of illness, chemoprophylaxis can be considered. The most effective preventive medication in this case is the antimicrobial also used for therapy, taken in half the therapeutic dosage daily while in the area of risk. However, the majority of travellers should not use this approach.(ABSTRACT TRUNCATED AT 250 WORDS)
对于那些从高度工业化地区前往热带和亚热带发展中地区的人来说,患腹泻的几率约为40%。在大多数情况下,细菌性病原体是导致疾病的原因。在墨西哥内陆的夏季月份(该药物已在此地区得到广泛研究),对这些病原体活性最强的抗菌药物是复方新诺明(甲氧苄啶/磺胺甲恶唑),而在其他地区或其他时间则使用氟喹诺酮类药物,直到有数据表明复方新诺明在此处也适用。有风险的人应该随身携带一种治疗旅行者腹泻症状的药物和一种合适的抗菌药物。在出现第三次不成形大便时,建议旅行者通过补充液体和盐分(大多数情况下,加了咸饼干的调味矿泉水就足够了)、对症治疗和抗菌治疗来自我治疗。其中,抗菌治疗是最重要的组成部分,可单次大剂量给药,或每日给药一到两次,持续3天。对于无发热、非痢疾性患者,最佳治疗方法可能是洛哌丁胺联合抗菌药物。如果出现发热或痢疾症状,则应单独使用抗菌药物。在特殊情况下,如果无法遵守饮食限制,且行程因疾病甚至不能有丝毫变动时,可以考虑进行化学预防。在这种情况下,最有效的预防性药物也是用于治疗的抗菌药物,在处于风险地区时,按治疗剂量的一半每日服用。然而,大多数旅行者不应采用这种方法。(摘要截选至250词)